These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34793697)

  • 1. Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN.
    Fayer S; Horton C; Dines JN; Rubin AF; Richardson ME; McGoldrick K; Hernandez F; Pesaran T; Karam R; Shirts BH; Fowler DM; Starita LM
    Am J Hum Genet; 2021 Dec; 108(12):2248-2258. PubMed ID: 34793697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
    Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
    J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional impact of BRCA1 BRCT domain variants using multiplexed DNA double-strand break repair assays.
    Adamovich AI; Diabate M; Banerjee T; Nagy G; Smith N; Duncan K; Mendoza Mendoza E; Prida G; Freitas MA; Starita LM; Parvin JD
    Am J Hum Genet; 2022 Apr; 109(4):618-630. PubMed ID: 35196514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking evolution of BRCA1-associated breast cancer.
    Jonkers J
    Cancer Discov; 2012 Jun; 2(6):486-8. PubMed ID: 22684454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
    Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
    Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary pathways in BRCA1-associated breast tumors.
    Martins FC; De S; Almendro V; Gönen M; Park SY; Blum JL; Herlihy W; Ethington G; Schnitt SJ; Tung N; Garber JE; Fetten K; Michor F; Polyak K
    Cancer Discov; 2012 Jun; 2(6):503-11. PubMed ID: 22628410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
    Jhuraney A; Velkova A; Johnson RC; Kessing B; Carvalho RS; Whiley P; Spurdle AB; Vreeswijk MP; Caputo SM; Millot GA; Vega A; Coquelle N; Galli A; Eccles D; Blok MJ; Pal T; van der Luijt RB; Santamariña Pena M; Neuhausen SL; Donenberg T; Machackova E; Thomas S; Vallée M; Couch FJ; Tavtigian SV; Glover JN; Carvalho MA; Brody LC; Sharan SK; Monteiro AN;
    J Med Genet; 2015 Apr; 52(4):224-30. PubMed ID: 25643705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating thousands of PTEN variant activity and abundance measurements reveals variant subgroups and new dominant negatives in cancers.
    Matreyek KA; Stephany JJ; Ahler E; Fowler DM
    Genome Med; 2021 Oct; 13(1):165. PubMed ID: 34649609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
    Lyra PCM; Nepomuceno TC; de Souza MLM; Machado GF; Veloso MF; Henriques TB; Dos Santos DZ; Ribeiro IG; Ribeiro RS; Rangel LBA; Richardson M; Iversen ES; Goldgar D; Couch FJ; Carvalho MA; Monteiro ANA
    Genet Med; 2021 Feb; 23(2):306-315. PubMed ID: 33087888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reclassification of
    Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
    J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
    Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
    Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA Repair Function Scores for 2172 Variants in the BRCA1 Amino-Terminus.
    Diabate M; Islam MM; Nagy G; Banerjee T; Dhar S; Smith N; Adamovich AI; Starita LM; Parvin JD
    bioRxiv; 2023 Apr; ():. PubMed ID: 37090572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrated Deep-Mutational-Scanning Approach Provides Clinical Insights on PTEN Genotype-Phenotype Relationships.
    Mighell TL; Thacker S; Fombonne E; Eng C; O'Roak BJ
    Am J Hum Genet; 2020 Jun; 106(6):818-829. PubMed ID: 32442409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
    Caputo SM; Golmard L; Léone M; Damiola F; Guillaud-Bataille M; Revillion F; Rouleau E; Derive N; Buisson A; Basset N; Schwartz M; Vilquin P; Garrec C; Privat M; Gay-Bellile M; Abadie C; Abidallah K; Airaud F; Allary AS; Barouk-Simonet E; Belotti M; Benigni C; Benusiglio PR; Berthemin C; Berthet P; Bertrand O; Bézieau S; Bidart M; Bignon YJ; Birot AM; Blanluet M; Bloucard A; Bombled J; Bonadona V; Bonnet F; Bonnet-Dupeyron MN; Boulaire M; Boulouard F; Bouras A; Bourdon V; Brahimi A; Brayotel F; Bressac de Paillerets B; Bronnec N; Bubien V; Buecher B; Cabaret O; Carriere J; Chiesa J; Chieze-Valéro S; Cohen C; Cohen-Haguenauer O; Colas C; Collonge-Rame MA; Conoy AL; Coulet F; Coupier I; Crivelli L; Cusin V; De Pauw A; Dehainault C; Delhomelle H; Delnatte C; Demontety S; Denizeau P; Devulder P; Dreyfus H; d'Enghein CD; Dupré A; Durlach A; Dussart S; Fajac A; Fekairi S; Fert-Ferrer S; Fiévet A; Fouillet R; Mouret-Fourme E; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Goldbarg V; Goussot V; Guibert V; Guillerm E; Guy C; Hardouin A; Heude C; Houdayer C; Ingster O; Jacquot-Sawka C; Jones N; Krieger S; Lacoste S; Lallaoui H; Larbre H; Laugé A; Le Guyadec G; Le Mentec M; Lecerf C; Le Gall J; Legendre B; Legrand C; Legros A; Lejeune S; Lidereau R; Lignon N; Limacher JM; Doriane Livon ; Lizard S; Longy M; Lortholary A; Macquere P; Mailliez A; Malsa S; Margot H; Mari V; Maugard C; Meira C; Menjard J; Molière D; Moncoutier V; Moretta-Serra J; Muller E; Nevière Z; Nguyen Minh Tuan TV; Noguchi T; Noguès C; Oca F; Popovici C; Prieur F; Raad S; Rey JM; Ricou A; Salle L; Saule C; Sevenet N; Simaga F; Sobol H; Suybeng V; Tennevet I; Tenreiro H; Tinat J; Toulas C; Turbiez I; Uhrhammer N; Vande Perre P; Vaur D; Venat L; Viellard N; Villy MC; Warcoin M; Yvard A; Zattara H; Caron O; Lasset C; Remenieras A; Boutry-Kryza N; Castéra L; Stoppa-Lyonnet D
    Am J Hum Genet; 2021 Oct; 108(10):1907-1923. PubMed ID: 34597585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/2 missense mutations and the value of in-silico analyses.
    Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
    Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships.
    Mighell TL; Evans-Dutson S; O'Roak BJ
    Am J Hum Genet; 2018 May; 102(5):943-955. PubMed ID: 29706350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing.
    Yamamoto Y; Kanai M; Kou T; Sugiyama A; Nakamura E; Miyake H; Yamada T; Nishigaki M; Kondo T; Murakami H; Torishima M; Matsumoto S; Kosugi S; Muto M
    J Hum Genet; 2020 Jan; 65(2):125-132. PubMed ID: 31628423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
    Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
    BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.